


DOCKET NUMBER  
PETITION RULE PRM 35-9  
(54 FR 38239)



Hahnemann University

205

'89 NOV 17 A8:23

November 3, 1989

OFFICE  
DOCKETING AND SERVICE  
BRANCH

Department of  
Radiation Oncology and  
Nuclear Medicine  
Division of  
Nuclear Medicine

Secretary of the Commission  
U.S. Nuclear Regulatory Commission  
Docketing and Service Branch, Docket # PRM-35-9  
Washington, DC 20555

215 448 7676  
215 448 7674

Broad & Vine  
Philadelphia, PA  
19102-1192

Dear Mr. Secretary:

I am writing to express my support for the Petition for Rulemaking filed by the American College of Nuclear Physicians and the Society of Nuclear Medicine. I am a practicing Nuclear Medicine technician at Hahnemann University Hospital in Philadelphia, Pennsylvania. I am deeply concerned over the revised 10 CFR 35 regulations (effective April, 1987) governing the medical use of byproduct material as they significantly impact my ability to practice high-quality Nuclear Medicine/Nuclear Pharmacy and are preventing me from providing optimized care to individual patients.

The NRC should recognize that the FDA does allow, and often encourages, other clinical uses of approved drugs, and actively discourages the submission of physician-sponsored IND's that describe new indications for approved drugs. The package insert was never intended to prohibit physicians from deviating from it for other indications; on the contrary, such deviation is necessary for growth in developing new diagnostic and therapeutic procedures. In many cases, manufacturers will never go back to the FDA to revise a package insert to include a new indication because it is not required by the FDA and there is simply no economic incentive to do so.

Currently, the regulatory provisions in Part 35 (35.100, 35.200, 35.300, and 33.17(a)(4)) do not allow practices which are legitimate and legal under FDA regulations and State medicine and pharmacy laws. These regulations therefore inappropriately interfere with the practice of medicine, which directly contradicts the NRC's Medical Policy statement against such interference.

The NRC should not strive to construct proscriptive regulations to cover all aspects of medicine, nor should it attempt to regulate radiopharmaceutical use. Instead, the NRC should rely on the expertise of the FDA, State

8911220353 891103  
PDR PRM  
35-9 PDR


JS10

Boards of Pharmacy, State Boards of Quality Assurance, the Joint Commission on Accreditation of Healthcare Organizations, radiation safety committees, institutional Q/A review procedures, and most importantly, the professional judgement of physicians and pharmacists who have been well-trained to administer and prepare these materials.

Since the NRC's primary regulatory focus appears to be based on the unsubstantiated assumption that misadministrations, particularly those involving diagnostic radiopharmaceuticals, pose a serious threat to the public health and safety, I strongly urge the NRC to pursue a comprehensive study by a reputable scientific panel, such as the National Academy of Sciences or the NCRP, to assess the radiobiological effects of misadministrations from Nuclear Medicine diagnostic and therapeutic studies. I firmly believe that the results of such a study will demonstrate that the NRC's efforts to impose more and more stringent regulations are unnecessary and not cost-effective in relation to the extremely low health risks of these studies.

In closing, I strongly urge the NRC to adopt the ACNP/SNM Petition for Rulemaking as expeditiously as possible.

Sincerely,



Mary Ann Medori  
Chief Technologist,  
Division of Nuclear Medicine,  
Hahnemann University Hospital  
Philadelphia, PA.